A Multicentre, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of Retigabine Immediate-release (IR) in Asian Adults With Partial Onset Seizures (Extension of Study RTG114855) [EXTENSION OF 700220875]
Latest Information Update: 06 Jan 2024
At a glance
- Drugs Retigabine (Primary)
- Indications Partial epilepsies
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 01 May 2022 According to a Form 6-K, 2022, company SEC filing, GlaxoSmithKline has changed its name to GSK.
- 11 Oct 2017 Status changed from active, no longer recruiting to completed.
- 12 Jan 2017 Planned End Date changed from 1 Dec 2017 to 1 Sep 2017.